Safety and Efficacy of Galvus in Elderly Type 2 Diabetes Patients
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 431 participants.
Also called NCT01257451
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 431 participants
- Sponsor
- Registry
-
NCT01257451
-
- Other papers using this trial's data
- Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Belgium, Bulgaria, Finland, Germany, Slovakia, Spain, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01257451. Randomized; quadruple masking; primary purpose treatment. Start 2010-12 (registry gives no type); primary completion 2012-03 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Efficacy of Galvus in Elderly Type 2 Diabetes Patients
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Vildagliptin
- Intervention (Drug)
- Placebo
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct01257451- Content hash
e673635545577cb975cf3489aeac957e99d032d21a34865fc75d8ae0b1c50209